CN102675380A - 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物 - Google Patents

结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物 Download PDF

Info

Publication number
CN102675380A
CN102675380A CN2012101116538A CN201210111653A CN102675380A CN 102675380 A CN102675380 A CN 102675380A CN 2012101116538 A CN2012101116538 A CN 2012101116538A CN 201210111653 A CN201210111653 A CN 201210111653A CN 102675380 A CN102675380 A CN 102675380A
Authority
CN
China
Prior art keywords
methyl
glucopyranosyl
fluorophenyl
crystal type
semihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012101116538A
Other languages
English (en)
Inventor
野村纯弘
川西英治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38973167&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102675380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN102675380A publication Critical patent/CN102675380A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

本发明涉及结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物。一种新颖的结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物，并具有有利的特性，特征在于其X-射线粉末衍射图谱和/或其红外线图谱。

Description

结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物
本申请是2009年5月21日进入中国的申请号为200780043154.7(PCT/JP2007/073729，国际申请日2007年12月3日)的专利申请“结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物”的分案申请。
技术领域
本发明涉及可用做钠依赖性葡萄糖转运体(sodium-dependent glucose transporter)抑制剂的结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物、其制备与分离的方法、包含该化合物及医药上可接受的载体的医药组合物、以及治疗的医药方法。
背景技术
专利WO2005/012326小册子公开为钠依赖性葡萄糖转运体(SGLT)抑制剂的化合物群，及这些化合物对于处理糖尿病、肥胖、糖尿病并发症等的治疗用途。描述于专利WO2005/012326小册子的式(I)的1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯：
Figure BDA0000153660660000011
一般而言，为了商业用途，重要的是产物应具备良好的操作性质。另外，亦需要制造纯质与结晶型的该产物，使配方可符合严格的医药上的要求与规格。
且理想的是该产物应为可易于过滤与容易干燥的型式。另外，经济上理想的是无须特殊保存条件即可在一段延长的时间内为稳定的产物。
但要从有机溶剂获得式(I)化合物的结晶型存在困难。
现已发现可以商业规模可重现的方法产生结晶型式(I)化合物的半水合物。
发明内容
本发明提供式(I)化合物的半水合物结晶型做为新颖的材料，特别是以医药上可接受的型式。
附图说明
图1为式(I)化合物的半水合物的结晶的X-射线粉末衍射图谱。
图2为式(I)化合物的半水合物的结晶的红外线图谱。
具体实施方式
本发明的发明人已发现可从含水的溶剂中结晶出式(I)化合物，且该式(I)化合物的半水合物的结晶型具备良好的操作性质与特性。
据此，本发明涉及：
1.一种结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物。
2.一种结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物，特征在于粉末X-射线衍射图谱(powder x-ray diffraction pattern)，该图谱包括使用CuKα放射测量的下述2θ值：4.36±0.2、13.54±0.2、16.00±0.2、19.32±0.2及20.80±0.2。
3.一种结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物，其具有与图1所示实质上相同的X-射线粉末衍射图谱。
4.一种结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物，其具有与图2所示实质上相同的IR图谱(infra-red spectrum)。
5.一种用以制备结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物的方法，其包括形成1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的溶液，并利用沉淀或再结晶从该溶液结晶该半水合物。
6.一种医药组合物，包括有效量的结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物及医药上可接受的载体。
7.一种用于治疗或延缓糖尿病、糖尿病视网膜病变、糖尿病神经病变、糖尿病肾病变、延迟性伤口愈合、胰岛素阻抗性、高血糖症、高胰岛素血症、脂肪酸的血中浓度升高、甘油的血中浓度升高、高血脂症、肥胖、高甘油三酯血症、X症候群(syndrome X)、糖尿病并发症、动脉粥状硬化症或高血压的进展或发病的方法，其包括投药治疗有效量的结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物。
如所述，本发明包含某些固态结晶型。存在用于表征该型式的多种方法，且本发明不应被所选择的方法、或用来特征化本发明化合物的设备而限制。例如，以X-射线衍射图谱而言，在实验图谱中，该衍射波峰强度可有所变化，如已知于本技术领域，主要起因于所制备样品的优选定向(该结晶的非任意定向)。因此，熟悉本领域技术的人员可了解，本发明的范畴必须考量到特征的变化度。
X-射线粉末衍射图谱
本发明(I)的结晶型可通过其X-射线粉末衍射图谱来表征。该化合物(I)的半水合物的结晶型的X-射线衍射图谱是以X-射线衍射仪(RINT-TTR，Rigaku，Tokyo，Japan)，使用CuKα放射来测量。X-射线粉末衍射的方法如下：
扫瞄速度：2.00度/分钟。
目标：CuKα。
电压：50仟伏特(kV)。
电流：300毫安培(mA)。
扫瞄范围：自3至40.0度。
取样宽度：0.0200度。
红外线图谱
本发明的结晶型在矿物油中的红外线图谱包括下列主要波峰：1626、1600、1549、与1507cm-1。
结晶型化合物(I)的半水合物的红外线图谱，是伴随以纵轴为透射率(％)且横轴为波数(cm-1)的图式而显示。
热重量分析(thermogravimetric analysis)
已观察到本发明的结晶型会以半水合物型式而存在。本发明的结晶的理论水含量为1.98％。对于本发明的结晶型的热重量分析显示1.705％的重量损失。
热重量分析的方法如下：秤重约8毫克的化合物(I)的半水合物，并移至TG-50(Shimadzu，Japan)的铝制槽架(cell holder)，接着，以5℃/分钟的加热速率测得结晶型化合物(I)半水合物的热重量(TG)热曲线。典型的测量范围是自环境温度至150℃。
本发明亦提供化合物(I)的半水合物的结晶型的制备方法，其是包括形成化合物(I)的溶液并从该溶液沉淀出结晶型。
典型地，可自以下的混合物获得化合物(I)的半水合物的结晶型：式(I)的化合物、良溶剂及水、任选含有的不良溶剂。
有时候，某些杂质会作用为结晶抑制剂，且杂质需以常规方法移除，如硅胶柱层析。然而，该式(I)化合物的半水合物的结晶型甚至可自相对不纯的化合物(I)获得。
本发明亦提供包括化合物(I)的半水合物的结晶型及医药上可接受的载体的医药组合物。
本发明的结晶型化合物具有作为钠依赖性葡萄糖转运体抑制剂的活性，并显示极佳的降血糖效果。
本发明的结晶型预期在以下方面有用：治疗、预防或延缓糖尿病(1型与2型糖尿病等)、糖尿病并发症(如糖尿病视网膜病变、糖尿病神经病变、糖尿病肾病变)、餐后高血糖症、延迟性伤口愈合、胰岛素阻抗性、高血糖症、高胰岛素血症、脂肪酸的血中浓度升高、甘油的血中浓度升高、高血脂症、肥胖、高甘油三酯血症、X症候群、动脉粥状硬化症或高血压的进展或发病。
本发明的结晶型或其医药上可接受的盐类可以口服或非肠道投药，并可以适当的医药制剂型式而使用。对于口服投药的适当医药制剂包含，例如，固态制剂如片剂、粒剂、胶囊、及粉末，或液态制剂、悬浮制剂、乳化制剂等。对于非肠道投药的适当医药制剂包含，例如，栓剂；注射制剂或静脉点滴制剂，利用注射用蒸馏水、生理食盐水溶液或葡萄糖水溶液；及吸入制剂。
此处的医药组合物将于每剂量单位，即片剂、胶囊、粉末、注射剂、栓剂、一茶匙量(teaspoonful)等，包含活性成分自约0.01毫克/千克至约100毫克/千克体重(优选自约0.01毫克/千克至约50毫克/千克；且更优选自约0.01毫克/千克至约30毫克/千克)，且可给予剂量自约0.01毫克/千克/天至约100毫克/千克/天(优选自约0.01毫克/千克/天至约50毫克/千克/天，且更优选自约0.01毫克/千克/天至约30毫克/千克/天)。治疗描述于本发明的病症的方法也可使用包括如此处定义的结晶型及医药上可接受的载体的医药组合物而实施。该剂量型将包含活性成分自约0.01毫克/千克至约100毫克/千克(优选自约0.01毫克/千克至约50毫克/千克，且更优选自约0.01毫克/千克至约30毫克/千克)，并可构成适合所选择的投药模式的任何型式。然而，该剂量可依投药途径、个体的需求、欲治疗症状的严重度、及所使用的化合物而不同。可采用于每日投药或后周期性用药(po st-periodic dosing)的用法。
若需要时，本发明结晶型可与一种或多种的其他抗糖尿病剂、抗高血糖剂、和/或其他疾病治疗剂组合使用。本发明化合物与该其他治疗剂可以相同剂型、或分开的口服剂型或注射投药。
该治疗剂的剂量可依，例如，年龄、体重、病患症状、投药途径、与剂量型式而不同。
该医药组合物可以口服投药至哺乳类，包含人类、猿、狗，以例如片剂、胶囊、粒剂、或粉末，或非肠道投药的注射剂型、或鼻内投药、或皮肤贴剂型的剂量型式。
可自以下的混合物制备该式(I)化合物的半水合物的结晶型：该化合物(I)、良溶剂与水、任选含有的不良溶剂。
已发现为适当的良溶剂的实例包含酮类(如丙酮、2-丁酮)、酯类(如乙酸乙酯、乙酸甲酯)、醇类(如甲醇、乙醇、异丙醇)，与该溶剂的混合物。不良溶剂的实例包含烷类(如己烷、庚烷)、芳族烃类(如苯、甲苯)、醚类(如***、二甲基醚、二异丙基醚)与这些溶剂的混合物。
该式(I)化合物的半水合物的结晶型的一个优选制剂，典型地，包括使依据专利WO2005/012326小册子所描述的方法所制备的式(I)的粗产物或非晶形化合物溶解于良溶剂中(如酮类或酯类)，并加入水及不良溶剂(如烷类或醚类)至该所得溶液，接着过滤。
在可溶于水的良溶剂的情况中，无须使用不良溶剂，且可将水加入该式(I)化合物于良溶剂中的溶液，依此，可降低该式(I)化合物在该溶液中的溶解性。
在使用不良溶剂的情况中，水的优选用量是对该式(I)化合物为1至10摩尔当量(molar equivalent)，良溶剂的优选用量是水的体积的10至100倍，且该不良溶剂的优选用量是该良溶剂的体积的0.1至10倍。
形成该式(I)化合物的半水合物的结晶型的精确条件可依经验而决定。
在该条件下，优选可在降低的、常温的、或升高的温度下进行结晶作用。
该式(I)化合物的半水合物的结晶型明显较非晶型化合物容易分离，且可在冷却后从该结晶作用的基质过滤、并洗涤和干燥。此外，本发明的结晶型较式(I)化合物的非晶型更为稳定。
实施例
实施例1：结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2- 噻吩基甲基]苯半水合物
依描述于WO 2005/012326中的相似方法制备1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯。
Figure BDA0000153660660000081
在氩气气氛中、于-67至-70℃，将正-丁基锂(1.6M己烷溶液，50.0毫升)滴入5-溴-1-[5-(4-氟苯基)-2-噻吩基甲基]-2-甲基苯(1，28.9克)于四氢呋喃(480毫升)与甲苯(480毫升)的溶液中，且将该混合物于相同温度搅拌20分钟。将2(34.0克)于甲苯(240毫升)的溶液于相同温度滴入，且将混合物于相同温度进一步搅拌1小时。接着，将甲基磺酸(21.0克)于甲醇(480毫升)的溶液滴入，并将所得混合物回温至室温并搅拌17小时。混合物于冰-水冷却中放凉，并加入饱和碳酸氢钠水溶液。混合物以乙酸乙酯萃取，并以浓盐水洗涤合并的有机层并以硫酸镁干燥。滤除不溶物并减压挥发溶剂。残余物以甲苯(100毫升)-己烷(400毫升)磨碎，获得1-(1-甲氧基吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯(3)(31.6克)。APCI-Mass m/z 492(M+NH4)。
(2)在氩气气氛中，利用干冰-丙酮浴冷却3(63.1克)与三乙基硅烷(46.4克)在二氯甲烷(660毫升)中的溶液，并向其中滴入三氟化硼·***的复合物(50.0毫升)，且于相同温度搅拌混合物。将混合物回温至0℃并搅拌2小时。于相同温度下，加入饱和碳酸氢钠水溶液(800毫升)，并搅拌混合物30分钟。减压挥发有机溶剂，并将残余物注入水中并以乙酸乙酯萃取两次。有机层以水洗涤两次，以硫酸镁干燥并以活性碳处理。滤除不溶物并减压挥发溶剂。残余物溶解于乙酸乙酯(300毫升)中，并加入二***(600毫升)与H2O(6毫升)。混合物于室温搅拌过夜，并收集沉淀物，以乙酸乙酯-二***(1∶4)洗涤，并于室温减压干燥以获得1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物(33.5克)的无色结晶。mp 98-100℃。APCI-Mass m/z 462(M+NH4)。
1H-NMR(DMSO-d6)δ2.26(3H，s)，3.13-3.28(4H，m)，3.44(1H，m)，3.69(1H，m)，3.96(1H，d，J＝9.3Hz)，4.10，4.15(each 1H，d，J＝16.0 Hz)，4.43(1H，t，J＝5.8 Hz)，4.72(1H，d，J＝5.6 Hz)，4.92(2H，d，J＝4.8Hz)，6.80(1H，d，J＝3.5 Hz)，7.11-7.15(2H，m)，7.18-7.25(3H，m)，7.28(1H，d，J＝3.5Hz)，7.59(2H，dd，J＝8.8，5.4Hz).Anal.Calcd.for C24H25FO5S·0.5H2O：C，63.56；H，5.78；F，4.19；S，7.07.Found：C，63.52；H，5.72；F，4.08；S，7.00.
实施例2
1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的非晶型粉末(1.62克)溶于丙酮(15毫升)中，并于其中加入H2O(30毫升)及晶种。混合物于室温搅拌18小时，并收集沉淀物，以丙酮-H2O(1∶4，30毫升)洗涤，并在室温减压干燥以获得1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物(1.52克)的无色结晶。mp 97-100℃。

Claims (6)

1.一种结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物。
2.根据权利要求1所述的结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物，其中所述结晶型在矿物油中的IR图谱包括下列主要波峰：1626、1600、1549、与1507cm-1。
3.根据权利要求1所述的结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物，其具有与图2所示实质上相同的IR图谱。
4.一种用以制备根据权利要求1所述的结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物的方法，其包括形成1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的溶液，并利用沉淀或再结晶将该半水合物从该溶液结晶。
5.一种医药组合物，其包括有效量的根据权利要求1所述的结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物及医药上可接受的载体。
6.根据权利要求1所述的结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物用于制备以下药物的用途，所述药物用于治疗或延缓糖尿病、糖尿病视网膜病变、糖尿病神经病变、糖尿病肾病变、延迟性伤口愈合、胰岛素阻抗性、高血糖症、高胰岛素血症、脂肪酸的血中浓度升高、甘油的血中浓度升高、高血脂症、肥胖、高甘油三酯血症、X症候群、糖尿病并发症、动脉粥状硬化症或高血压的进展或发病。
CN2012101116538A 2006-12-04 2007-12-03 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物 Pending CN102675380A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86842606P 2006-12-04 2006-12-04
US60/868,426 2006-12-04
JP2006327019 2006-12-04
JP2006-327019 2006-12-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2007800431547A Division CN101573368B (zh) 2006-12-04 2007-12-03 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物

Publications (1)

Publication Number Publication Date
CN102675380A true CN102675380A (zh) 2012-09-19

Family

ID=38973167

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2007800431547A Active CN101573368B (zh) 2006-12-04 2007-12-03 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物
CN2012100910385A Pending CN102675299A (zh) 2006-12-04 2007-12-03 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物
CN2012101116538A Pending CN102675380A (zh) 2006-12-04 2007-12-03 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN2007800431547A Active CN101573368B (zh) 2006-12-04 2007-12-03 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物
CN2012100910385A Pending CN102675299A (zh) 2006-12-04 2007-12-03 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物

Country Status (34)

Country Link
US (2) US7943582B2 (zh)
EP (1) EP2102224B2 (zh)
JP (1) JP5159788B2 (zh)
KR (1) KR101146095B1 (zh)
CN (3) CN101573368B (zh)
AR (3) AR064099A1 (zh)
AU (1) AU2007329895C1 (zh)
BR (1) BRPI0718882B8 (zh)
CA (1) CA2671357C (zh)
CL (1) CL2007003487A1 (zh)
CO (1) CO6210719A2 (zh)
CR (1) CR10861A (zh)
DK (1) DK2102224T4 (zh)
EA (1) EA017103B1 (zh)
EC (1) ECSP099489A (zh)
ES (1) ES2456640T5 (zh)
GT (1) GT200900151A (zh)
IL (1) IL199032A (zh)
ME (1) ME01829B (zh)
MX (1) MX2009005857A (zh)
MY (1) MY153702A (zh)
NO (1) NO344354B1 (zh)
NZ (1) NZ577545A (zh)
PA (1) PA8759401A1 (zh)
PE (3) PE20130591A1 (zh)
PL (1) PL2102224T5 (zh)
PT (1) PT2102224E (zh)
RS (1) RS53274B2 (zh)
SI (1) SI2102224T2 (zh)
SV (1) SV2009003285A (zh)
TW (1) TWI403325B (zh)
UY (1) UY30730A1 (zh)
WO (1) WO2008069327A1 (zh)
ZA (1) ZA200903941B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104402946A (zh) * 2014-11-17 2015-03-11 连云港恒运医药科技有限公司 卡格列净中间体及其无定形的制备方法

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30730A1 (es) † 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
HUE035130T2 (en) * 2007-09-10 2018-05-02 Janssen Pharmaceutica Nv A method for preparing compounds useful as SGLT inhibitors
AR073118A1 (es) 2008-08-22 2010-10-13 Theracos Inc Procesos para la preparacion de inhibidores de sglt2 y formas cristalinas del mismo.
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
AU2010212867B2 (en) 2009-02-13 2013-05-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
JP5658751B2 (ja) * 2009-07-10 2015-01-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンのための結晶化方法
US8869918B2 (en) 2009-10-07 2014-10-28 Longyear Tm, Inc. Core drilling tools with external fluid pathways
DK2488515T3 (en) * 2009-10-14 2017-02-27 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
AR079438A1 (es) 2009-12-09 2012-01-25 Panacea Biotec Ltd Derivados de azucar, composiciones farmaceuticas y sus usos
CN102115468B (zh) * 2009-12-31 2014-06-11 上海特化医药科技有限公司 一种2,5-二取代噻吩化合物的合成方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2552442A1 (en) 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
MX339570B (es) * 2010-05-11 2016-05-31 Janssen Pharmaceutica Nv Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
US20130052266A1 (en) 2010-05-11 2013-02-28 Mitsubishi Tanabe Pharma Corporation TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN102970981A (zh) * 2010-07-06 2013-03-13 詹森药业有限公司 糖尿病协同治疗制剂
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2697218T1 (sl) * 2011-04-13 2016-07-29 Janssen Pharmaceutica Nv Postopek za pripravo spojin, koristnih kot zaviralci sglt2
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
WO2012163990A1 (en) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2014530186A (ja) 2011-09-13 2014-11-17 パナセア バイオテック リミテッド 新規ｓｇｌｔ阻害剤
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112014010574A2 (pt) 2011-10-31 2017-05-02 Scinopharm Taiwan Ltd formas cristalinas e não cristalinas de inibidores sglt2
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
CN103965267A (zh) * 2013-01-24 2014-08-06 江苏豪森医药集团连云港宏创医药有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯与L-苯丙氨酸共晶物及其制备方法
EP3466431B1 (en) 2013-03-14 2023-11-15 MSD International GmbH Crystalline forms and methods for preparing sglt2 inhibitors
CA2907079C (en) 2013-03-15 2021-06-22 Janssen Pharmaceutica Nv Combination of canagliflozin and probenecid for the treatment of hyperuricemia
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
CA2911261A1 (en) * 2013-05-08 2014-11-13 Lek Pharmaceuticals D.D. Novel crystalline hydrates of 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
WO2014195966A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited Amorphous form of canagliflozin and process for preparing thereof
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
CN103641822B (zh) * 2013-10-21 2016-06-08 江苏奥赛康药业股份有限公司 一种卡格列净化合物及其药物组合物
WO2015071761A2 (en) * 2013-11-11 2015-05-21 Crystal Pharmatech Co., Ltd. Crystalline forms b, c, and d of canagliflozin
CN103588762A (zh) * 2013-11-27 2014-02-19 苏州晶云药物科技有限公司 坎格列净的新晶型及其制备方法
CN111494357A (zh) 2013-12-17 2020-08-07 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
MX2016009421A (es) * 2014-01-23 2016-09-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales caninos.
EP3099328A1 (en) 2014-01-31 2016-12-07 Janssen Pharmaceutica NV Methods for the treatment and prevention of renal disorders and fatty liver disorders
US10174010B2 (en) 2014-03-19 2019-01-08 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
HUE050095T2 (hu) 2014-04-01 2020-11-30 Boehringer Ingelheim Vetmedica Gmbh Anyagcsere-rendellenességek kezelése lófélékben
CN103980262B (zh) * 2014-04-01 2016-06-22 天津大学 卡格列净的b晶型及其结晶制备方法
CN103980261B (zh) * 2014-04-01 2016-06-29 天津大学 卡格列净的a晶型及其结晶制备方法
CN103896930B (zh) * 2014-04-02 2016-08-17 安徽联创生物医药股份有限公司 卡格列净半水合物药用晶型的制备方法
EP2933255A1 (en) 2014-04-17 2015-10-21 LEK Pharmaceuticals d.d. Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
CN103936726B (zh) * 2014-04-18 2016-06-15 王军 晶体、制备方法及其用途
CN103936800A (zh) * 2014-05-08 2014-07-23 安徽联创药物化学有限公司 1-(1-甲氧基吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的制备方法
EP2947077A1 (en) 2014-05-19 2015-11-25 LEK Pharmaceuticals d.d. Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides
CN105330706B (zh) * 2014-06-05 2019-04-16 江苏豪森药业集团有限公司 卡格列净中间体的制备方法
CN105319294B (zh) * 2014-06-20 2021-03-30 重庆医药工业研究院有限责任公司 一种分离测定卡格列净及其有关物质的方法
CN104761546A (zh) * 2014-06-21 2015-07-08 山东富创医药科技有限公司 一种新颖的 (1s)-1,5-脱氢-1-[3-[[5-(4-氟苯基)-2-噻吩基]甲基]-4-甲基苯基]-d-葡萄糖醇晶型及其制备方法
WO2016016774A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited Crystalline forms of canagliflozin
EP2990029A1 (en) 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
WO2016035042A1 (en) 2014-09-05 2016-03-10 Mylan Laboratories Ltd Process for the preparation of canagliflozin
CZ2014634A3 (cs) 2014-09-16 2016-03-23 Zentiva, K.S. Komplexy canagliflozinu a cyklodextrinů
CN105753910A (zh) * 2014-12-16 2016-07-13 康普药业股份有限公司 一种卡格列净中间体的制备方法
CN104530023A (zh) * 2014-12-25 2015-04-22 重庆医药工业研究院有限责任公司 一种卡格列净晶型i及其制备方法
CN104945392A (zh) * 2015-01-27 2015-09-30 江苏嘉逸医药有限公司 结晶型卡格列净一水合物、制备方法及其应用
CN104530024B (zh) 2015-02-04 2017-08-08 上海迪赛诺药业有限公司 1‑(β‑D‑吡喃葡糖基)‑4‑甲基‑3‑[5‑(4‑氟苯基)‑2‑噻吩基甲基]苯的晶型及其制备方法
EP3262039A4 (en) * 2015-02-27 2018-11-14 MSN Laboratories Private Limited Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof
JP2018087140A (ja) * 2015-02-27 2018-06-07 田辺三菱製薬株式会社 １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンの新規結晶
WO2016142950A1 (en) * 2015-03-11 2016-09-15 Harman Finochem Limited A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form
ES2817526T3 (es) 2015-05-22 2021-04-07 Janssen Pharmaceutica Nv Forma cristalina anhidra de (1S)-1,5-anhidro-1-[3-[[5-(4-fluorofenil)-2-tienil]metil]-4-metilfenil]-D-glucitol
CN106279134A (zh) * 2015-06-23 2017-01-04 中美华世通生物医药科技（武汉）有限公司 卡格列净单晶及其制备方法和用途
CZ2015435A3 (cs) 2015-06-25 2017-01-04 Zentiva, K.S. Pevné formy amorfního canagliflozinu
ES2896101T3 (es) 2015-09-15 2022-02-23 Laurus Labs Ltd Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
WO2017064679A1 (en) * 2015-10-15 2017-04-20 Lupin Limited Process for the preparation of amorphous canagliflozin
WO2017071813A1 (en) * 2015-10-30 2017-05-04 Zaklady Farmaceutyczne Polpharma Sa Process for the preparation of a pharmaceutical agent
CZ2015824A3 (cs) * 2015-11-20 2017-05-31 Zentiva, K.S. Krystalická forma Canagliflozinu a způsob její přípravy
CN108368096B (zh) 2015-12-21 2021-12-10 詹森药业有限公司 用于获得坎格列净半水合物晶体的结晶程序
CN105541818A (zh) * 2016-03-04 2016-05-04 浙江华海药业股份有限公司 一种卡格列净水合物新晶型及其制备方法
CN107540706A (zh) * 2016-06-28 2018-01-05 山东诚创医药技术开发有限公司 伊格列净中间体的制备方法
WO2018020506A1 (en) 2016-07-25 2018-02-01 Natco Pharma Ltd Process for the preparation of amorphous form of canagliflozin
WO2018073154A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
CN108017626A (zh) * 2016-11-04 2018-05-11 上海奥博生物医药技术有限公司 一种坎格列净半水合物新晶型
CN106588898A (zh) 2017-02-20 2017-04-26 浙江华海药业股份有限公司 一种卡格列净无定型的制备方法
KR20200014406A (ko) 2017-06-12 2020-02-10 얀센 파마슈티카 엔.브이. Ii형 진성 당뇨병을 갖는 환자에서 심혈관 사건을 감소시키거나 예방하는 방법
CN109553649B (zh) * 2017-09-26 2020-12-04 北大方正集团有限公司 一种卡格列净中间体的制备方法
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
TW202103709A (zh) 2019-03-26 2021-02-01 比利時商健生藥品公司 用於治療患有慢性腎臟病之對象的方法
JP7441946B2 (ja) 2019-11-28 2024-03-01 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 非ヒト動物の乾乳におけるｓｇｌｔ－２阻害剤の使用
CA3167531A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
JP2023523596A (ja) 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
CN113943329A (zh) * 2020-07-16 2022-01-18 尚科生物医药（上海）有限公司 一种坎格列净中间体的非对映异构体的制备方法
EP4206212A1 (en) 2020-09-30 2023-07-05 Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. Sglt-2 inhibitor sarcosine co-crystal, preparation method therefor and use thereof
KR20240041966A (ko) 2021-07-28 2024-04-01 베링거잉겔하임베트메디카게엠베하 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
WO2023006747A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012326A1 (en) * 2003-08-01 2005-02-10 Tanabe Seiyaku Co., Ltd. Novel compounds having inhibitory activity against sodium-dependant transporter
CN101573368B (zh) * 2006-12-04 2012-06-20 田边三菱制药株式会社 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160861A (en) * 1977-10-03 1979-07-10 Merck & Co., Inc. Method for the separation of antibiotic macrolides
US4584369A (en) * 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
JP2544609B2 (ja) 1986-10-07 1996-10-16 和光純薬工業株式会社 Ｔｃｎｑ錯体
EP0355750B1 (en) 1988-08-19 1995-01-25 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
JPH04253974A (ja) 1991-02-05 1992-09-09 Ishihara Sangyo Kaisha Ltd スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤
US5149838A (en) * 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
GB9208161D0 (en) 1992-04-14 1992-05-27 Pfizer Ltd Indoles
US5334225A (en) 1992-07-15 1994-08-02 Kao Corporation Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US6297363B1 (en) * 1993-02-12 2001-10-02 Nomura Co., Ltd. Glycoside indoles
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
DE69634045T2 (de) 1995-10-31 2005-05-19 Eli Lilly And Co., Indianapolis Antithrombotische diamine
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JPH09263549A (ja) 1996-01-25 1997-10-07 Fujisawa Pharmaceut Co Ltd ベンゼン誘導体の製造法
DK0850948T3 (da) * 1996-12-26 2002-07-29 Tanabe Seiyaku Co Propiophenonderivater og fremgangsmåde til fremstilling deraf
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JPH10324632A (ja) 1997-03-25 1998-12-08 Takeda Chem Ind Ltd 医薬組成物
JP2000034239A (ja) 1998-07-16 2000-02-02 Asahi Glass Co Ltd トリフルオロメチル化芳香族化合物の製造方法
JP3857429B2 (ja) 1998-07-17 2006-12-13 ポーラ化成工業株式会社 含硫黄抗真菌剤
US20020032164A1 (en) * 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
CA2401697A1 (en) 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
BR0109323A (pt) * 2000-03-17 2002-12-24 Kissei Pharmaceutical Derivados de gluco piranosiloxi benzil benzeno, composições medicinais contendo os mesmos e intermediários para a preparação dos derivados
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
EP1338603B1 (en) 2000-11-02 2010-01-20 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
US6476352B2 (en) * 2000-12-18 2002-11-05 General Electric Company Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor
ES2326158T3 (es) 2000-12-28 2009-10-02 Kissei Pharmaceutical Co., Ltd. Derivados de glucopiranosiloxipirazol y su utilizacion como medicamentos.
DE60230591D1 (de) * 2001-02-26 2009-02-12 Kissei Pharmaceutical Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
WO2002068440A1 (fr) 2001-02-27 2002-09-06 Kissei Pharmaceutical Co., Ltd. Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
CA2439448C (en) 2001-03-02 2012-05-22 University Of Western Ontario Polymer precursors of radiolabeled compounds, and methods of making and using the same
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2444481A1 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
CA2672001A1 (en) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
GB0112122D0 (en) 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
JP4399254B2 (ja) 2001-06-20 2010-01-13 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
JPWO2003011880A1 (ja) 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
AU2002337302A1 (en) * 2001-10-24 2003-05-06 Michael Burton Chromogenic enzyme substrates and method for detecting beta-d-ribofuranosidase activity
NZ552216A (en) 2001-11-16 2008-07-31 Bioform Medical Inc Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
US6617313B1 (en) * 2002-03-13 2003-09-09 Council Of Scientific And Industrial Research Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
NZ561993A (en) 2002-04-18 2008-09-26 Astrazeneca Ab Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
BR0310006A (pt) 2002-08-09 2005-02-15 Taisho Pharmaceutical Co Ltd Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
US20040102477A1 (en) 2002-08-23 2004-05-27 Dr. Reddy's Laboratories Limited Polymorphic forms of (S)-Repaglinide and the processes for preparation thereof
WO2004019958A1 (ja) 2002-08-27 2004-03-11 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
BR0317929A (pt) * 2003-01-03 2006-04-11 Bristol Myers Squibb Co métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
US7202350B2 (en) 2003-03-14 2007-04-10 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
EP1637539B1 (en) 2003-06-20 2012-01-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
EA009768B1 (ru) * 2003-08-01 2008-04-28 Янссен Фармацевтика Нв Замещенные конденсированные гетероциклические с-гликозиды
AR048377A1 (es) * 2003-08-01 2006-04-26 Janssen Pharmaceutica Nv Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
UA86042C2 (en) * 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
CA2549025A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
CA2549017A1 (en) * 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides
WO2005030127A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2006108842A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US20090221592A1 (en) 2005-07-25 2009-09-03 Ellison Martha E Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
WO2007054978A2 (en) 2005-11-10 2007-05-18 Jubilant Organosys Limited Process for preparing paroxetine hydrochloride hemihydrate
EP1842850A1 (en) 2006-03-23 2007-10-10 Sandoz AG Rosiglitazone hydrochloride hemihydrate
HUE035130T2 (en) † 2007-09-10 2018-05-02 Janssen Pharmaceutica Nv A method for preparing compounds useful as SGLT inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012326A1 (en) * 2003-08-01 2005-02-10 Tanabe Seiyaku Co., Ltd. Novel compounds having inhibitory activity against sodium-dependant transporter
CN1829729A (zh) * 2003-08-01 2006-09-06 田边制药株式会社 新颖化合物
CN101573368B (zh) * 2006-12-04 2012-06-20 田边三菱制药株式会社 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104402946A (zh) * 2014-11-17 2015-03-11 连云港恒运医药科技有限公司 卡格列净中间体及其无定形的制备方法
CN104402946B (zh) * 2014-11-17 2018-01-02 连云港恒运药业有限公司 卡格列净中间体及其无定形的制备方法

Also Published As

Publication number Publication date
PL2102224T5 (pl) 2021-11-08
SV2009003285A (es) 2010-08-17
CA2671357A1 (en) 2008-06-12
PL2102224T3 (pl) 2014-07-31
DK2102224T3 (da) 2014-04-22
PT2102224E (pt) 2014-04-07
ZA200903941B (en) 2010-08-25
AU2007329895C1 (en) 2014-03-13
PE20110841A1 (es) 2011-11-24
JP5159788B2 (ja) 2013-03-13
WO2008069327A1 (en) 2008-06-12
NO20091778L (no) 2009-09-04
CA2671357C (en) 2011-11-01
UY30730A1 (es) 2008-07-03
ES2456640T3 (es) 2014-04-23
TWI403325B (zh) 2013-08-01
CR10861A (es) 2009-07-17
BRPI0718882B1 (pt) 2021-03-23
EA017103B1 (ru) 2012-09-28
IL199032A (en) 2012-12-31
US20110212905A1 (en) 2011-09-01
NZ577545A (en) 2011-08-26
CN102675299A (zh) 2012-09-19
AU2007329895B2 (en) 2011-09-08
KR101146095B1 (ko) 2012-05-16
JP2010511602A (ja) 2010-04-15
CO6210719A2 (es) 2010-10-20
EP2102224B1 (en) 2014-02-12
EP2102224B2 (en) 2021-08-04
AU2007329895A1 (en) 2008-06-12
BRPI0718882A2 (pt) 2014-09-16
AR118450A2 (es) 2021-10-06
NO344354B1 (no) 2019-11-11
PE20081201A1 (es) 2008-09-04
ES2456640T5 (es) 2021-12-02
AR064099A1 (es) 2009-03-11
BRPI0718882B8 (pt) 2021-05-25
US7943582B2 (en) 2011-05-17
MX2009005857A (es) 2009-06-12
GT200900151A (es) 2012-01-17
MY153702A (en) 2015-03-13
US20080146515A1 (en) 2008-06-19
CN101573368B (zh) 2012-06-20
PE20130591A1 (es) 2013-05-12
SI2102224T1 (sl) 2014-03-31
CN101573368A (zh) 2009-11-04
RS53274B2 (sr) 2021-10-29
CL2007003487A1 (es) 2008-03-14
AR107510A2 (es) 2018-05-09
PA8759401A1 (es) 2009-04-23
TW200829259A (en) 2008-07-16
EA200970540A1 (ru) 2009-10-30
DK2102224T4 (da) 2021-10-11
EP2102224A1 (en) 2009-09-23
KR20090086282A (ko) 2009-08-11
ECSP099489A (es) 2009-08-28
SI2102224T2 (sl) 2021-11-30
RS53274B (en) 2014-08-29
US8513202B2 (en) 2013-08-20
ME01829B (me) 2014-12-20

Similar Documents

Publication Publication Date Title
CN101573368B (zh) 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物
CN101910189B (zh) 吡唑衍生物的单癸二酸盐
CN101817862A (zh) 熊果酸-3-O-β-D-吡喃葡萄糖醛酸苷及其衍生物、其制备方法及医药用途
CN104230907A (zh) 晶体制备方法及其用途
EP2168955B1 (en) Sleep-improving agent
CN101541821B (zh) 1,6-双[3-(3-羧甲基苯基)-4-(2-α-D-吡喃甘露糖基-氧基)-苯基]己烷的晶形
CN104945455B (zh) 香豆素苷类化合物、其制法和药物组合物与用途
CN113493374B (zh) Sirt1受体激动剂及包含其的药物
CN108699094A (zh) 一种钠依赖性葡萄糖共转运蛋白抑制剂的胺溶剂合物及其制备方法和应用
CN104447721A (zh) 坎格列净无水化合物
JPH06122623A (ja) 抗腫瘍剤
CN104447722A (zh) 坎格列净化合物
CN104945392A (zh) 结晶型卡格列净一水合物、制备方法及其应用
CN104693192A (zh) 一种化合物的晶型a及其制备方法和应用
CN104610208B (zh) (1s)‑1,6‑二脱氧‑1‑[4‑甲氧基‑3‑(反式‑4‑正丙基环己基)甲基苯基]‑d‑吡喃葡萄糖的晶型a及其制备方法和应用
KR20080104063A (ko) 치환 페닐알칸산의 신규 결정 및 제조 방법
CN101514159B (zh) 用于防治糖尿病的化合物及其合成制备方法与药物用途
CN101397315B (zh) 香豆素苷类化合物、其制法和其药物组合物与用途
JPH04182446A (ja) ベンゼン誘導体
CN104693190A (zh) 一种化合物的晶型b及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120919